HC Wainwright & Co. Initiates Coverage On Larimar Therapeutics with Buy Rating, Announces Price Target of $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has initiated coverage on Larimar Therapeutics with a Buy rating and set a price target of $15.
October 02, 2024 | 10:12 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. has initiated coverage on Larimar Therapeutics with a Buy rating and a price target of $15, indicating a positive outlook.
The initiation of coverage with a Buy rating and a specific price target of $15 by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and could lead to an increase in the stock price of Larimar Therapeutics in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100